Compare Hims and Hers Health Inc (HIMS) vs HP Inc (HPQ) Price & Performance

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.

HPQ trades at $28.72, down 3.62% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue grew to $55.3B in 2025, though net margins compressed to 4.45%. The stock offers a dividend yield near 4% and trades at attractive valuations with a P/E of 10.77 and P/S of 0.48. Recent news highlights AI-driven cost savings and a potential 2027 upgrade cycle, while institutional activity shows mixed positioning adjustments.

Outlook: HPQ presents value with low multiples and dividend income, but faces PC market volatility and margin pressure. Risks include competitive threats and debt levels, while catalysts include AI product adoption. Analyst consensus is mixed with a hold rating, but technical strength and earnings consistency support cautious optimism for patient investors.